Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)

Q: What does CUSIP 67080M103 represent in this 13F holders report?

CUSIP 67080M103 is the security identifier for NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2023?

127 institutional investors reported NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2023. Use the holders table for investor-level position and value details.

CUSIP: 67080M103

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 103,174,603
Total 13F shares: 46,078,653
Share change: +1,038,697
Total reported value: $475,525,962
Put/Call ratio: 19%
Price per share: $10.32
Number of holders: 127
Value change: +$17,732,104
Number of buys: 65
Number of sells: 62

Quarterly Holders Quick Answers

What is CUSIP 67080M103?
CUSIP 67080M103 identifies NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 67080M103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock Finance, Inc.	13F	Company	4.4%	4,518,554	$35,515,834	—	30 Sep 2023	13F
Third Rock Ventures III, L.P.	3/4/5	10%+ Owner	— class O/S missing	3,509,348	$35,104,359	—	06 May 2021	3/4/5
BAKER BROS. ADVISORS LP	13F	Company	3.8%	3,882,125	$30,513,503	—	30 Sep 2023	13F
WASATCH ADVISORS LP	13F	Company	3.5%	3,564,616	$28,017,882	—	30 Sep 2023	13F
Deep Track Capital, LP	13F	Company	2.9%	2,997,830	$23,562,944	—	30 Sep 2023	13F
Redmile Group, LLC	13F	Company	2.8%	2,848,827	$22,391,780	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	2.6%	2,714,845	$21,338,682	—	30 Sep 2023	13F
ARK Investment Management LLC	13F	Company	2.5%	2,593,047	$20,381,349	—	30 Sep 2023	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2.3%	2,377,978	$18,692,000	—	30 Sep 2023	13F
COLUMN GROUP L P	3/4/5	10%+ Owner	— class O/S missing	1,442,739	$14,431,862	—	07 May 2021	3/4/5
Bain Capital Life Sciences Investors, LLC	13F	Company	1.8%	1,822,883	$14,327,860	—	30 Sep 2023	13F
STATE STREET CORP	13F	Company	1.7%	1,774,068	$13,944,174	—	30 Sep 2023	13F
Boxer Capital, LLC	13F	Company	1.2%	1,224,892	$9,627,651	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1%	1,045,285	$8,216,849	—	30 Sep 2023	13F
S.c.a. Candriam	13F	Individual	0.94%	968,110	$7,609,345	—	30 Sep 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.93%	958,043	$7,530,998	—	30 Sep 2023	13F
Pictet Asset Management Holding SA	13F	Company	0.87%	897,809	$7,056,779	—	30 Sep 2023	13F
Soleus Capital Management, L.P.	13F	Company	0.79%	814,000	$6,398,040	—	30 Sep 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.64%	663,260	$5,213,223	—	30 Sep 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.55%	568,576	$4,469,007	—	30 Sep 2023	13F
DAFNA Capital Management LLC	13F	Company	0.54%	556,695	$4,375,623	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.53%	546,450	$4,295,097	—	30 Sep 2023	13F
NORTHERN TRUST CORP	13F	Company	0.43%	440,852	$3,465,098	—	30 Sep 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.35%	363,526	$2,857,314	—	30 Sep 2023	13F
BESSEMER GROUP INC	13F	Company	0.35%	357,287	$2,809,000	—	30 Sep 2023	13F
FMR LLC	13F	Company	0.31%	320,907	$2,522,329	—	30 Sep 2023	13F
ArrowMark Colorado Holdings LLC	13F	Company	0.31%	314,762	$2,474,029	—	30 Sep 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.28%	288,157	$2,264,914	—	30 Sep 2023	13F
WestHill Financial Advisors, Inc.	13F	Company	0.27%	283,333	$2,226,997	—	30 Sep 2023	13F
SUVRETTA CAPITAL MANAGEMENT, LLC	13F	Company	0.27%	280,760	$2,206,774	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.25%	253,413	$1,991,826	—	30 Sep 2023	13F
Affinity Asset Advisors, LLC	13F	Company	0.24%	250,000	$1,965,000	—	30 Sep 2023	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.24%	247,080	$1,942,049	—	30 Sep 2023	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.23%	240,608	$1,891,179	—	30 Sep 2023	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.19%	195,420	$1,536,000	—	30 Sep 2023	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.18%	183,923	$1,445,635	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0.17%	172,002	$1,351,936	—	30 Sep 2023	13F
Bank of New York Mellon Corp	13F	Company	0.17%	170,286	$1,338,448	—	30 Sep 2023	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.16%	163,623	$1,286,077	—	30 Sep 2023	13F
Pierre Beaurang	3/4/5	Chief Business Officer	— mixed-class rows	127,558 mixed-class rows	$1,210,335	—	10 Aug 2021	3/4/5
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.14%	145,053	$1,140,117	—	30 Sep 2023	13F
GLOBEFLEX CAPITAL L P	13F	Company	0.14%	140,500	$1,104,330	—	30 Sep 2023	13F
MARSHALL WACE, LLP	13F	Company	0.12%	127,509	$1,002,222	—	30 Sep 2023	13F
LOS ANGELES CAPITAL MANAGEMENT LLC	13F	Company	0.12%	125,839	$989,095	—	30 Sep 2023	13F
Rafferty Asset Management, LLC	13F	Company	0.1%	98,839	$776,875	—	30 Sep 2023	13F
RAYMOND JAMES & ASSOCIATES	13F	Company	0.09%	97,988	$770,176	—	30 Sep 2023	13F
Jasper Ridge Partners, L.P.	13F	Company	0.09%	95,711	$752,288	—	30 Sep 2023	13F
Trexquant Investment LP	13F	Company	0.09%	88,066	$692,199	—	30 Sep 2023	13F
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group	13F	Company	0.08%	85,000	$668,100	—	30 Sep 2023	13F
Swiss National Bank	13F	Company	0.08%	84,800	$666,528	—	30 Sep 2023	13F

Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q4 2023

As of 31 Dec 2023, Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by 127 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 46,078,653 shares. The largest 10 holders included BlackRock Inc., BAKER BROS. ADVISORS LP, Redmile Group, LLC, ARK Investment Management LLC, MORGAN STANLEY, Deep Track Capital, LP, WASATCH ADVISORS LP, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, and Bain Capital Life Sciences Investors, LLC. This page lists 127 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

129

Q4 2023 holders

127

Holder diff

-2

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.